Tevogen Inc. (TVGN)

Tevogen Inc. announced that Susan Podlogar resigned from the Board of Directors effective November 2, 2026. In response, the Board reduced its size from six to five members and appointed current director Lindee Goh to serve on the Audit Committee, also effective immediately. The company operates in the biotechnology sector.

Tevogen Inc. entered into a First Amendment to its Loan Agreement with The Patel Family, LLP on October 27, 2026. The amendment extends the borrowing period for the unsecured line of credit from May 31, 2027, to May 31, 2029, and increases the aggregate post-amendment borrowing limit to $28.6 million. On November 2, 2026, Tevogen repaid the entire outstanding principal balance of $7.4 million plus accrued interest by issuing 1,000,000 principal shares and 23,733 interest shares at a fixed price of $7.40 per share. Additionally, the company granted CEO Ryan Saadi a restricted stock award covering 50,000,000 shares that vest only upon achieving $1.0 billion in aggregate revenue by December 31, 2031. Tevogen Inc. operates in the biotechnology industry, focusing on developing treatments for neurological disorders.